| Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. | |
| | |
MedLine Citation:
|
PMID: 21981575 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Patients with common variable immunodeficiency (CVID) are at high risk of developing immune thrombocytopenia (ITP) and/or autoimmune haemolytic anaemia (AHA). Given their underlying immunodeficiency, immunosuppressive treatment of these manifestations may increase the risk of infection. To assess efficacy and safety of rituximab in patients with CVID-associated ITP/AHA, a multicentre retrospective study was performed. Thirty-three patients, 29 adults and four children, were included. Patients received an average of 2·6 treatments prior to rituximab including steroids, intravenous immunoglobulin and splenectomy (21%). The median ITP/AHA duration at time of first rituximab administration was 12 months [range 1-324] and the indication for using rituximab was ITP (22 cases), AHA (n = 5) or both (n = 7); 1 patient was treated sequentially for ITP and then AHA. The overall initial response rate to rituximab was 85% including 74% complete responses. After a mean follow-up of 39 ± 30 months after rituximab first administration, 10 of the initial responders relapsed and re-treatment with rituximab was successful in 7/9. Severe infections occurred after rituximab in eight adults (24%), four of whom were not on immunoglobulin replacement therapy. In conclusion, rituximab appears to be highly effective and relatively safe for the management of CVID-associated severe immune cytopenias. |
| | |
Authors:
|
Delphine Gobert; James B Bussel; Charlotte Cunningham-Rundles; Lionel Galicier; Agnès Dechartres; Alice Berezne; Bernard Bonnotte; Thierry DeRevel; Christophe Auzary; Roland Jaussaud; Claire Larroche; Alain LeQuellec; Marc Ruivard; Pascal Seve; Amar Smail; Jean-François Viallard; Bertrand Godeau; Olivier Hermine; Marc Michel |
Related Documents
:
|
20190685 - Recurrence of helicobacter pylori infection 1 year after successful eradication: a pros... 8221815 - Six-month maintenance treatment of duodenal ulcer with sucralfate: influence on antral ... 3726395 - Taeniasis unresponsive to a single dose of niclosamide: case report of persistent infec... 22205675 - The kurtzke edss rank stability increases 4 years after the onset of multiple sclerosis... 21334015 - Outcomes of inferior sinus venosus defect repair. 6753115 - Pirenzepine in duodenal ulcer. a six week, double-blind study. |
Publication Detail:
|
Type: Journal Article; Multicenter Study Date: 2011-10-08 |
Journal Detail:
|
Title: British journal of haematology Volume: 155 ISSN: 1365-2141 ISO Abbreviation: Br. J. Haematol. Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-10-28 Completed Date: 2012-03-01 Revised Date: 2013-04-01 |
Medline Journal Info:
|
Nlm Unique ID: 0372544 Medline TA: Br J Haematol Country: England |
Other Details:
|
Languages: eng Pagination: 498-508 Citation Subset: IM |
Copyright Information:
|
© 2011 Blackwell Publishing Ltd. |
Affiliation:
|
Department of Internal Medicine, Hôpital Henri Mondor, Créteil, Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Anemia, Hemolytic, Autoimmune / drug therapy*, immunology Antibodies, Monoclonal, Murine-Derived / adverse effects, therapeutic use* Child Common Variable Immunodeficiency / blood, drug therapy* Female Humans Male Middle Aged Retrospective Studies Thrombocytopenia / drug therapy*, immunology Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
P01 AI061093/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal, Murine-Derived; 0/rituximab |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Recruitment facilitation can promote coexistence and buffer population growth in metacommunities.
Next Document: Carbon Nanofibers Decorated with Poly(furfuryl alcohol)-Derived Carbon Nanoparticles and Tetraethylo...